## REMARKS

Applicants request acceptance of the claims of the present application in view of the above amendments and the following remarks.

## **OBJECTIONS**

As requested by the Examiner, the following statement has been incorporated to specify the dose limitation: "at a dose of less than 30 mg/kg".

As requested by the Examiner, Applicants have amended claim 32 to overcome the Examiner's objection.

## REJECTIONS

Claim 28 hase been rejected under 35 U.S.C. 102(a) as being anticipated by the Landry et al reference. Claim 28 has been cancelled along with claims 33-35 that depended on it.

Applicants kindly request that the claims be accepted in view of the remarks and amendments provided above. No new matter has be introduced by these amendments.

06/13/ 2005 11:55 AM

## CLAIMS WITH MARKUPS

1-28. (Cancelled)

subject in need a pharmaceutical comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier, comprising preparing the pharmaceutical composition comprising S-tofisopam, prodrug or pharmaceutically acceptable salt thereof and a pharmaceutically effective carrier and administering the pharmaceutical composition at a dose of less than 30 mg/kg to said subject.

33-35. (Cancelled)

06/13/ 2065 11:55